Drug intelligence / Profile preview

RLD2006

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

RLD2006 is a pharmaceutical agent presented in tablet form. It has been evaluated in an open-label, randomized, single-dose crossover clinical study (NCT05191563) to assess its pharmacokinetics, safety, and tolerability. The study involved healthy subjects and compared the co-administration of RLD2006 with RLD2001-2 against a fixed-dose combination of HCP1904.

Other names: chlorthalidone

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on RLD2006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2006.

Explore the full profile